# Daqing Cai

> Daqing Cai is a Series B investor at Sherpa Healthcare Partners backing Medical and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sherpa Healthcare Partners](https://shizune.co/investors/profile/sherpa-venture-capital)
- Location: Beijing, China
- Total investments: 6
- Last investment: Apr 2024
- Lead investor: 50%
- Last updated: Aug 2026

Daqing Cai is a Series B investor at Sherpa Healthcare Partners in Beijing focused on Medical and Biotechnology. Daqing Cai is based out of Beijing and is the founder and Managing partner, Partner of Sherpa Healthcare Partners. Daqing previously worked at Legend Capital as a Managing Director. Daqing Cai attended the University of California, Berkeley.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 50% |
| Biotechnology | 3 | 50% |
| Health Care | 2 | 33% |
| Genetics | 1 | 17% |
| Biopharma | 1 | 17% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 33% |
| Seed | 1 | 17% |
| Series C | 1 | 17% |
| Series D | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 33% |
| United States | 2 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Brise Pharma | Brise Pharma operates in the scientific research and technical service industry. | $20M | Seed | Apr 22, 2024 |  |
| Brise Pharma | Brise Pharma operates in the scientific research and technical service industry. | $20M | Seed | Apr 22, 2024 |  |
| Huihe Healthcare | Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China. |  | Series B | Sep 12, 2021 |  |
| Alamar Biosciences | Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California. | $80M | Series B | Sep 08, 2021 |  |
| Bionano Genomics | Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $53M | Series C | Nov 20, 2014 |  |
| Bionano Genomics | Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $9.9M | Series D |  |  |

6 of 6 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 5 deals together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 2 deals together
- [China Gas Yijing](https://shizune.co/investors/profile/china-gas-yijing) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 2 deals together
- [Shunxi Fund](https://shizune.co/investors/profile/shunxi-fund) — VC Fund, 2 deals together

## About Sherpa Healthcare Partners

VC Fund · Beijing, China

Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.

5 contacts available at Sherpa Healthcare Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Daqing Cai | founder and Managing partner | https://shizune.co/investors/profile/cai-daqing |
| Darren Cai | Founder & Managing Partner | https://shizune.co/investors/profile/darren-cai |
| He Zhu | Vice President | https://shizune.co/investors/profile/he-zhu |
| Ouyang Xiangyu | Co-Founder & Managing Partner | https://shizune.co/investors/profile/ouyang-xiangyu-b45d |
| Shi Yina | Managing Director | https://shizune.co/investors/profile/shi-yina |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Daqing Cai invest in?

Daqing Cai invests primarily in Medical, Biotechnology and Health Care startups, most often at Series B and Seed stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Daqing Cai last invest?

The most recent investment recorded for Daqing Cai closed in Apr 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co